LLY - 3 Biotech Stocks With a Lot to Prove at ASH 2019
It's nearly time for the annual get-together of the American Society of Hematology (ASH). There will be presentations from too many drugmakers for any one person to absorb, but at least three will be worthy of more attention than most.
A cellular cancer therapy from Celgene that Bristol-Myers Squibb (NYSE: BMY) hasn't quite paid for yet will finally get a day in the spotlight. An easy-to-swallow tablet from ArQule (NASDAQ: ARQL) will have a chance to shine. We'll also get a closer look at clinical data from a candidate Eli Lilly (NYSE: LLY) bought from Loxo Oncology earlier this year.
Image source: Getty Images.